Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
Status:
Completed
Trial end date:
2013-03-06
Target enrollment:
Participant gender:
Summary
This is a prospective, non-blinded randomized phase III trial. Patients will be
post-surgically stratified at inclusion first according to the participating institution,
then according to menopausal status and will be randomly assigned to receive either:
- TAC: Docetaxel 75 mg/m2 as a 1 hour intravenous (i.v.) infusion on day 1 every 3 weeks
(q3w) in combination with doxorubicin 50 mg/m2 as an i.v. bolus and cyclophosphamide 500
mg/m2 as an i.v. bolus on day 1 every 3 weeks.
- FAC: 5-fluorouracil 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks in combination
with doxorubicin 50 mg/m2 as an i.v. bolus and cyclophosphamide 500 mg/m2 as an i.v.
bolus on day 1 every 3 weeks.